Copyright © 2004 by the European Society of Cardiology.
Clinical research
Suppression of paroxysmal atrial tachyarrhythmias — results of the SOPAT trial
a Herzzentrum, Kardiologie, Universitäts-Klinikum Hamburg Eppendorf, Germany
b Institut für Medizinische Statistik, Universität Wien, Austria
c Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Germany
d Henstedt-Ulzburg, Germany
e The Medical University of Warsaw, Brodnowski Hospital, Poland
f Slovak Cardiovascular Institute, Bratislava, Slovak Republic
g Central Hospital of Warsaw, Poland
h Abbott GmbH, Ludwigshafen, Germany
Received February 19, 2004; revised May 14, 2004; accepted June 3, 2004 * Corresponding author (E-mail: patten{at}uke.uni-hamburg.de).
See page 1371 for the editorial comment on this article (doi:10.1016/j.ehj.2004.06.027)
AIM: The indication to treat paroxysmal atrial fibrillation (PAF) is controversial. The Suppression of Paroxysmal Atrial Tachyarrhythmias (SOPAT) trial was designed to answer the following questions: (1) What is the average rate of spontaneous events of symptomatic PAF with and without anti-arrhythmic medication? (2) what is the prevalence of severe side-effects? and (3) is the fixed combination of Quinidine+Verapamil inferior to the efficacy of sotalol or not?
METHODS AND RESULTS: Within 60 months 172 centres in Germany, Poland, and The Slovak Republic prospectively enrolled 1033 patients (mean age 60 years, 62% male) with documented frequent episodes of symptomatic PAF. Patients were randomised to either Quinidine+Verapamil 480/240 mg/d (high dose; 263 patients), Quinidine+Verapamil 320/160 mg/d (low dose; 255 patients), Sotalol 320 mg/d (264 patients) or placebo (251 patients), of which 1012 patients entered the intention-to-treat analysis. The primary endpoint was the time to first recurrence of symptomatic PAF or premature discontinuation. Secondary outcome parameters were the total number of symptomatic episodes and tolerability of the tested drugs. Patients were followed for a period of up to 12 months by daily and symptom-triggered trans-telephonic ECG-monitoring (Tele-ECG).
The mean time under treatment was 233±152 days. Regarding the primary endpoint, all active treatments were superior to placebo and not different from each other. A total of 756 patients reached the primary endpoint within 105.7±8.7 d (mean±SEM) in the placebo group, vs. Quinidine+Verapamil (high dose) (150.4±10 d, p=0.0061), vs. Quinidine+Verapamil (low dose) (148.9±10.6 d, p=0.0006), vs. Sotalol (145.6±93 d, p=0.0007). All three treatments were also effective in the reduction of AF burden (days with symptomatic AF [%] mean±SD, p vs. placebo): Quinidine+Verapamil (high dose) (3.4±12, p=0.0001), Quinidine+Verapamil (low dose) (4.5±12.3, p=0.008) and Sotalol (2.9±6.5, p=0.026) compared to placebo (6.1±13.5). A total of four deaths, 13 syncopes, and one ventricular tachycardia (VT) occurred during the active study period, of which one death and one VT were related to Quinidine/Verapamil.
CONCLUSION: Taken together, anti-arrhythmic therapy with the fixed combination of Quinidine+Verapamil is as effective as Sotalol in the reduction of the recurrence rate of symptomatic PAF with a low but definite risk of severe side-effects.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Quinidine rehabilitated and more lessons from the PAFAC and SOPAT anti-arrhythmic drug trials for the prevention of paroxysmal atrial fibrillation
- Norbert van Hemel
EHJ 2004 25: 1371-1373.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  A. J Morguet, P. Kuhnelt, A. Kallel, U. Rauch, and H.-P. Schultheiss Utilization of telemedicine by heart disease patients following hospitalization J Telemed Telecare, June 1, 2008; 14(4): 178 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schneider, R. Malisius, K. Krause, F. Lampe, E. Bahlmann, S. Boczor, M. Antz, S. Ernst, and K.-H. Kuck Strain rate imaging for functional quantification of the left atrium: atrial deformation predicts the maintenance of sinus rhythm after catheter ablation of atrial fibrillation Eur. Heart J., June 1, 2008; 29(11): 1397 - 1409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Steven, T. Rostock, B. Lutomsky, H. Klemm, H. Servatius, I. Drewitz, K. Friedrichs, R. Ventura, T. Meinertz, and S. Willems What is the real atrial fibrillation burden after catheter ablation of atrial fibrillation? A prospective rhythm analysis in pacemaker patients with continuous atrial monitoring Eur. Heart J., April 2, 2008; 29(8): 1037 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al. Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) Eur. Heart J., November 2, 2007; 28(22): 2803 - 2817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association Europace, November 1, 2007; 9(11): 1006 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]
|
|
|
|
|
|
E. Hoffmann, N. Sulke, N. Edvardsson, J. Ruiter, T. Lewalter, A. Capucci, A. Schuchert, S. Janko, J. Camm, and on behalf of the Atrial Fibrillation Therapy (AFT) New Insights Into the Initiation of Atrial Fibrillation: A Detailed Intraindividual and Interindividual Analysis of the Spontaneous Onset of Atrial Fibrillation Using New Diagnostic Pacemaker Features Circulation, April 25, 2006; 113(16): 1933 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med, April 10, 2006; 166(7): 719 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Veloso and A. A.V. de Paola Quinidine plus verapamil vs. quinidine alone to prevent recurrences of atrial fibrillation Eur. Heart J., August 1, 2005; 26(15): 1568 - 1569. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Falk Rate Control Is Preferable to Rhythm Control in the Majority of Patients With Atrial Fibrillation Circulation, June 14, 2005; 111(23): 3141 - 3150. [Full Text] [PDF]
|
|
|
|
|
|
N. van Hemel Quinidine rehabilitated and more lessons from the PAFAC and SOPAT anti-arrhythmic drug trials for the prevention of paroxysmal atrial fibrillation Eur. Heart J., August 2, 2004; 25(16): 1371 - 1373. [Full Text] [PDF]
|
|